object
intent
studi
examin
recoveri
individu
hospit
sever
acut
respiratori
syndrom
sar
year
follow
discharg
hospit
paramet
studi
includ
serum
level
sar
coronaviru
sarscov
igg
antibodi
test
lung
function
imag
data
evalu
chang
lung
fibrosi
addit
explor
incid
femor
head
necrosi
individu
recov
sar
subject
studi
clinic
diagnos
sar
patient
beij
china
test
regularli
serum
level
sarscov
igg
antibodi
lung
function
given
chest
xray
andor
high
resolut
computer
tomographi
hrct
examin
chines
pla
gener
hospit
month
follow
releas
hospit
individu
found
lung
diffus
abnorm
transfer
coeffici
carbon
monoxid
l
co
predict
valu
pred
receiv
regular
lung
function
test
hrct
examin
followup
phase
order
document
chang
lung
condit
patient
complain
joint
pain
given
magnet
reson
imag
mri
examin
femor
head
find
subject
patient
test
posit
serum
sarscov
igg
test
posit
patient
suffer
lung
diffus
abnorm
l
co
pred
patient
exhibit
lung
fibrot
chang
month
durat
studi
patient
lung
diffus
abnorm
examin
exhibit
improv
lung
function
fibrosi
detect
radiographi
individu
receiv
mri
examin
patient
show
sign
femor
head
necrosi
lack
seroposit
sarscov
individu
suggest
may
misdiagnos
case
among
subject
includ
studi
test
posit
serum
level
sarscov
igg
antibodi
decreas
significantli
month
hospit
discharg
addit
found
individu
lung
fibrosi
show
spontan
recoveri
final
subject
develop
femor
head
necrosi
sever
acut
respiratori
syndrom
sar
new
infecti
diseas
human
first
victim
sar
diagnos
businessman
citi
foshan
guangdong
provinc
china
sar
patient
may
present
spectrum
symptom
sign
rang
rel
asymptomat
fulmin
pneumon
death
lung
injuri
caus
sar
coronaviru
sarscov
one
main
clinic
manifest
sar
patient
significantli
affect
prognosi
regular
followup
survey
sar
patient
convalesc
phase
would
help
evalu
chang
acquir
immun
function
pulmonari
function
bone
joint
cours
time
present
report
relationship
prognosi
recoveri
degre
lung
injuri
caus
sarscov
addit
studi
serum
level
specif
igg
antibodi
sarscov
need
major
immunolog
protect
aid
recoveri
essenti
avoid
repeat
infect
sarscov
month
sinc
world
health
organ
offici
declar
global
outbreak
sar
control
present
studi
focus
dynam
chang
igg
antibodi
level
sarscov
lung
lesion
discharg
recov
sar
patient
measur
lung
function
imag
test
phenomenon
femor
head
necrosi
also
investig
sar
patient
complain
chronic
bone
joint
pain
one
year
followup
discharg
hospit
subject
studi
discharg
beij
xiaotangshan
hospit
beij
arm
polic
hospit
chines
pla
hospit
gave
inform
consent
subject
investig
clinic
diagnos
sar
patient
convalesc
phase
male
femal
averag
age
year
undergo
test
may
june
clinic
diagnosi
base
clinic
diagnosi
standard
sar
patient
issu
ministri
chines
public
health
particip
studi
met
specifi
criteria
discharg
hospit
first
visit
patient
given
routin
pulmonari
function
test
ventil
diffus
function
sensormed
pulmonari
function
test
apparatu
usa
chest
xray
examin
serum
sarscov
specif
antibodi
sarscov
igg
test
chines
pla
gener
hospit
beij
pr
china
individu
suspect
pulmonari
fibrot
chang
receiv
high
resolut
computer
tomographi
hrct
examin
lung
individu
complain
chronic
pain
bone
joint
difficulti
walk
receiv
femor
head
magnet
reson
imag
mri
examin
patient
return
month
first
visit
follow
one
visit
everi
month
serum
sarscov
igg
test
return
visit
neg
result
obtain
twice
consecut
case
regard
misdiagnosi
patient
undergo
followup
survey
patient
posit
sarscov
igg
abnorm
pulmonari
diffus
receiv
regular
pulmonari
function
test
show
pulmonari
fibrosi
imag
examin
receiv
regular
hrct
examin
individu
observ
avascular
necrosi
femor
head
receiv
mri
examin
month
later
epidemiolog
histori
individu
histori
close
contact
sar
patient
part
cluster
case
sar
clinic
evid
infect
patient
individu
histori
recent
travel
area
sar
case
report
within
week
secondari
infect
sar
case
found
symptom
sign
acut
onset
sar
gener
begin
prodrom
fever
temperatur
sometim
accompani
chill
myalgia
anthralgia
headach
fatigu
upper
respiratori
tract
symptom
catarrh
promin
although
cough
may
present
present
mainli
dri
cough
occasion
blood
streak
sputum
individu
chest
discomfort
sever
case
may
present
tachypnea
pant
even
respiratori
distress
gener
obviou
pulmonari
sign
among
sar
patient
wet
rale
sign
lung
consolid
well
decreas
respir
sign
pleural
effus
occasion
found
note
patient
show
initi
symptom
fever
especi
recent
surgeri
chronic
diseas
routin
laboratori
examin
white
blood
cell
count
gener
normal
normal
decreas
absolut
lymphocyt
count
typic
imag
profil
sar
multipl
patchi
opac
bilater
distribut
opac
usual
groundglass
appear
sometim
air
space
consolid
evolv
progress
cours
diseas
evolut
rapid
case
result
confluenc
lesion
larg
area
opacif
short
time
chest
radiolog
examin
neg
reexamin
day
done
suspect
case
accord
accord
sarscov
igg
antibodi
serum
specimen
recov
sar
patient
assay
bgigbi
biotech
compani
enzymelink
immunosorb
assay
elisa
kit
bgigbi
biotech
compani
beij
pr
china
well
contain
polystyren
micropl
strip
coat
two
recombin
sarscov
antigen
wellcharacter
recov
sar
patient
serum
sampl
diluent
buffer
incub
coat
well
min
well
wash
time
wash
buffer
dilutedenzymelabel
antihuman
igg
ad
well
incub
min
well
wash
time
wash
buffer
tetramethylbenzidin
substrat
ad
well
presenc
specif
antibodi
indic
yellow
color
develop
substrat
addit
reaction
termin
addit
hydrochlor
acid
intens
color
measur
spectrophotometr
nm
quantifi
amount
antibodi
specimen
optic
densiti
od
measur
compar
standard
calibr
curv
construct
lot
yield
concentr
valu
sampl
od
valu
posit
neg
control
determin
threshold
valu
igg
od
unit
calcul
mean
standard
deviat
sd
level
read
given
control
blood
donor
sera
sampl
od
threshold
valu
sampl
consid
posit
sarscov
igg
recov
sar
patient
underw
standard
pulmonari
function
test
sensormed
yorba
linda
usa
forc
expiratori
volum
second
fev
vital
capac
vc
forc
vital
capac
fvc
total
lung
capac
tlc
transfer
coeffici
carbon
monoxid
l
co
carbon
monoxid
diffus
constant
l
cov
measur
mean
singlebreath
test
hemoglobin
level
also
measur
adjust
l
co
valu
result
compar
ageand
sexmatch
control
express
percentag
predict
valu
pulmonari
function
regard
abnorm
l
co
less
predict
valu
pred
consid
diffus
deficit
frontal
chest
xray
radiograph
cxr
obtain
first
followup
visit
recov
sar
patient
abnorm
found
cxr
l
co
pred
despit
normal
cxr
patient
sent
hrct
scan
ge
light
speed
ge
usa
section
thick
gap
supin
posit
scan
inspir
second
per
scan
kv
cxr
hrct
imag
assess
three
radiologist
via
view
consol
three
radiologist
awar
patient
clinic
diagnosi
time
review
radiograph
final
conclus
establish
consensu
segment
lung
review
groundglass
opacif
interstiti
thicken
bronchiectasi
architectur
distort
abnorm
magnifi
mean
zoom
function
examin
intralobular
interstiti
interlobular
septal
peribronchovascular
interstiti
thicken
attent
also
paid
presenc
absenc
nodul
mass
cavit
calcif
emphysema
presenc
parenchym
band
irregular
interfac
bronchovascular
pleural
mediastin
thicken
interstitium
traction
bronchiectasi
consid
evid
fibrot
chang
mri
examin
done
use
signa
cvi
imag
ge
medic
system
milwauke
wi
usa
patient
complain
chronic
bone
joint
pain
coron
weight
spin
echo
time
repetit
tr
time
echo
te
scan
hip
done
abnorm
note
weight
imag
weight
sagitt
imag
coron
short
tau
invers
recoveri
invers
time
tr
te
turbospinecho
imag
fat
suppress
tr
te
obtain
imag
mm
thick
obtain
coron
studi
mm
thick
imag
obtain
sagitt
studi
osteonecrosi
diagnos
presenc
band
low
signal
intens
weight
imag
data
express
sd
unless
otherwis
indic
statist
analys
done
oneway
analysi
varianc
anova
studentnewmankeul
chisquar
test
multipl
comparison
use
statist
analysi
softwar
window
stata
statist
softwar
inc
usa
evalu
x
result
studi
statist
test
criterion
signific
p
valu
less
interv
hospit
discharg
first
followup
visit
day
rang
day
individu
particip
studi
patient
x
x
femor
head
avascular
necrosi
one
femor
head
ten
patient
show
first
stage
chang
secondari
chang
month
followup
visit
individu
obviou
chang
avascular
necrosi
patient
sinc
outbreak
sar
end
despit
great
effort
extend
mechan
clinic
characterist
prognosi
effect
therapeut
diseas
adequ
clarifi
sar
viru
antivir
therapi
highdos
glucocorticoid
use
treatment
caus
variou
degre
toxic
side
effect
includ
pulmonari
fibrosi
avascular
necrosi
femor
head
even
convalesc
phase
followup
survey
sar
patient
convalesc
phase
need
recogn
clinic
characterist
diseas
reevalu
therapeut
treatment
indic
emphas
import
epidemiolog
histori
clinic
manifest
chest
radiolog
chang
clinic
diagnosi
sar
diseas
cdc
sar
case
definit
especi
emphas
import
laboratori
criteria
confirm
sar
diagnosi
accomplish
detect
dynam
chang
titrat
specif
antibodi
sar
cov
posit
detect
sarscov
rna
pcr
contrast
chines
clinic
diagnosi
standard
mention
import
laboratori
sarscov
test
confirm
sar
diagnosi
might
result
misdiagnosi
sar
case
followup
examin
found
individu
posit
sarscov
igg
remain
posit
year
although
level
antibodi
decreas
gradual
therefor
inocul
sar
vaccin
infect
sar
viru
might
receiv
lifetim
immun
immun
result
chest
hrct
examin
sar
patient
convalesc
phase
show
mark
revers
pulmonari
fibrosi
figur
result
chest
hrct
examin
sar
patient
convalesc
phase
show
mark
revers
pulmonari
fibrosi
limit
durat
certainli
find
must
confirm
studi
regular
examin
pulmonari
function
cxr
found
pulmonari
fibrot
chang
abl
heal
fibrot
tissu
absorb
pulmonari
diffus
vc
improv
time
suggest
mechan
lung
injuri
lung
fibrosi
caus
sarscov
may
differ
pathophysiolog
process
compar
lung
diseas
idiopath
pulmonari
fibrosi
pulmonari
fibrosi
secondari
adult
respiratori
stress
syndrom
reason
clear
howev
followup
studi
found
groundglasslik
chang
hrct
imag
sar
patient
one
year
discharg
result
show
chang
lung
still
observ
convalesc
recent
concern
focus
complic
sar
convalesc
phase
avascular
necrosi
develop
femor
head
morbid
condit
report
sar
patient
mainland
china
among
patient
receiv
mri
examin
case
complic
necrosi
femor
head
differ
degre
caus
complic
includ
sar
drug
glucocorticoid
use
treatment
latter
import
former
nt
find
worsen
improv
avascular
necrosi
femor
head
patient
followup
examin
although
patient
receiv
magnetotherapi
hyperbar
oxygen
chamber
therapi
local
kerotherapi
chines
tradit
medicin
promot
local
blood
circul
appar
shortterm
therapeut
effect
method
recoveri
femor
head
conclus
sar
new
diseas
remain
unfamiliar
mankind
high
rate
morbid
mortal
acut
phase
signific
proport
patient
surviv
acut
ill
impair
overal
function
capac
health
statu
convalesc
phase
discharg
hospit
followup
survey
sar
patient
convalesc
phase
need
understand
clinic
characterist
diseas
find
suggest
follow
studi
patient
requir
longer
durat
includ
comprehens
assess
detect
appropri
manag
persist
emerg
sequela
type
investig
may
facilit
search
effect
therapeut
aid
ultim
conquer
diseas
thank
research
fund
nation
high
technolog
research
develop
program
china
program
note
indic
time
discharg
acut
ill
statist
analys
done
oneway
analysi
varianc
anova
studentnewmankeul
multipl
comparison
valu
given
mean
sd
compar
first
followup
exam
p
